A phase i clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 127, Issue 3, 2011, Pages 689-696

  Zaman, K ^a   Durando, X ^b   Baurain, J F ^c   Humblet, Y ^c   Mazzeo, F ^c   Bostnavaron, M ^d   Meheust, N ^d   Monnoyer Favrel, S ^d   MacHiels, J P ^c   Bauer, J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CENTRE JEAN PERRIN   (France)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Advanced stage; Breast cancer; Doxorubicin; Pharmacokinetics; Phase I; Vinflunine

Indexed keywords

ANTIEMETIC AGENT; DOXORUBICIN; DOXORUBICINOL; GRANULOCYTE COLONY STIMULATING FACTOR; LAXATIVE; VINFLUNINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; COLITIS; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIASTOLIC DYSFUNCTION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCORTICOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMATITIS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; VINBLASTINE;

EID: 79958256679     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1446-x     Document Type: Article

References (32)

1. DA Berry KA Cronin SK Plevritis DG Fryback L Clarke M Zelen JS Mandelblatt AY Yakovlev JD Habbema EJ Feuer 2005 Effect of screening and adjuvant therapy on mortality from breast cancer N Engl J Med 353 1784 1792 16251534 10.1056/NEJMoa050518 1:CAS:528:DC%2BD2MXhtFKrtLbN (Pubitemid 41549890)
2. P Francis J Crown A Di Leo M Buyse A Balil M Andersson B Nordenskjold I Lang R Jakesz D Vorobiof J Gutierrez G van Hazel S Dolci S Jamin B Bendahmane RD Gelber A Goldhirsch M Castiglione-Gertsch M Piccart-Gebhart 2008 Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial J Natl Cancer Inst 100 121 133 18182617 10.1093/jnci/djm287 1:CAS:528:DC%2BD1cXivVOnsr8%3D (Pubitemid 351480565)
3. S Beslija J Bonneterre HJ Burstein V Cocquyt M Gnant V Heinemann J Jassem WJ Kostler M Krainer S Menard T Petit L Petruzelka K Possinger P Schmid E Stadtmauer M Stockler S Van Belle C Vogel N Wilcken C Wiltschke CC Zielinski H Zwierzina 2009 Third consensus on medical treatment of metastatic breast cancer Ann Oncol 20 1771 1785 19608616 10.1093/annonc/mdp261 1:STN:280: DC%2BD1MjhvVCmtg%3D%3D
4. C Smigal A Jemal E Ward V Cokkinides R Smith HL Howe M Thun 2006 Trends in breast cancer by race and ethnicity: update 2006 CA Cancer J Clin 56 168 183 16737949 10.3322/canjclin.56.3.168 (Pubitemid 43847927)
5. J Bennouna JP Delord M Campone L Nguyen 2008 Vinflunine: a new microtubule inhibitor agent Clin Cancer Res 14 1625 1632 18347163 10.1158/1078-0432.CCR-07-2219 1:CAS:528:DC%2BD1cXjtlejtro%3D (Pubitemid 351469446)
6. J Bennouna P Fumoleau JP Armand E Raymond M Campone FM Delgado C Puozzo M Marty 2003 Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours Ann Oncol 14 630 637 12649112 10.1093/annonc/mdg174 1:STN:280:DC%2BD3s7jsVSitg%3D%3D (Pubitemid 41295094)
7. Fumoleau P, Cortes-Funes H, Taleb AB, Chan S, Campone M, Pouget JC, Tubiana-Hulin M, Slabber CF, Caroff-Paraiso I, Alberts AS, Ayed FB (2009) Phase 2 study of single-agent iv vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol (in press)
8. J Bennouna JL Breton JM Tourani C Ottensmeier M O'Brien P Kosmidis TE Huat MC Pinel C Colin JY Douillard 2006 Vinflunine-an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study Br J Cancer 94 1383 1388 16641911 10.1038/sj.bjc.6603106 1:CAS:528:DC%2BD28XksFKntbw%3D (Pubitemid 43772270)
9. PJ Souquet M Krzakowski R Ramlau XS Sun G Lopez-Vivanco C Puozzo JC Pouget MC Pinel R Rosell 2010 Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer Clin Lung Cancer 11 105 113 20199976 10.3816/CLC.2010.n.014 1:CAS:528:DC%2BC3cXkt1Sit7Y%3D
10. J Bellmunt C Theodore T Demkov B Komyakov L Sengelov G Daugaard A Caty J Carles A Jagiello-Gruszfeld O Karyakin FM Delgado P Hurteloup E Winquist N Morsli Y Salhi S Culine H von der Maase 2009 Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 4454 4461 19687335 10.1200/JCO.2008.20.5534 1:CAS:528:DC%2BD1MXhtlCnsrfI
11. M Campone H Cortes-Funes D Vorobiof M Martin CF Slabber E Ciruelos E Bourbouloux C Mendiola FM Delgado C Colin V Aslanis P Fumoleau 2006 Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy Br J Cancer 95 1161 1166 17031408 10.1038/sj.bjc.6603347 1:CAS:528:DC%2BD28XhtFChs7%2FJ (Pubitemid 44658478)
12. F Cardoso PL Bedard EP Winer O Pagani E Senkus-Konefka LJ Fallowfield S Kyriakides A Costa T Cufer KS Albain 2009 International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy J Natl Cancer Inst 101 1174 1181 19657108 10.1093/jnci/djp235 1:CAS:528:DC%2BD1MXhtFWhu73J
13. R Fossati C Confalonieri V Torri E Ghislandi A Penna V Pistotti A Tinazzi A Liberati 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women J Clin Oncol 16 3439 3460 9779724 1:CAS:528:DyaK1cXmvFGrurs%3D (Pubitemid 28481644)
14. A Hamilton G Hortobagyi 2005 Chemotherapy: what progress in the last 5 years? J Clin Oncol 23 1760 1775 15755984 10.1200/JCO.2005.10.034 1:CAS:528:DC%2BD2MXjtVCqu74%3D (Pubitemid 46211428)
15. Hill BT, Barret J-M, Fahy J, Kruczynski A (2001) In vitro and in vivo synergistic and additive effects of vinflunine, a novel fluorinated vinca alkaloid currently in phase ii trials, in combination with other anticancer drugs. Proc Am Soc Clin Oncol 20:Abstract 2138
16. C Le Tourneau JJ Lee LL Siu 2009 Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst 101 708 720 19436029 10.1093/jnci/djp079 1:CAS:528:DC%2BD1MXmtlyit7w%3D
17. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
18. Nguyen L. RS, Mentré F., Variol P. and Puozzo C (2002) Population pharmacokinetics of vinflunine from phase I data and evaluation of population sampling designs for further clinical development. PAGE Meeting, Paris:Abstract 334
19. S Eksborg HS Strandler F Edsmyr I Naslund P Tahvanainen 1985 Pharmacokinetic study of i.v. infusions of adriamycin Eur J Clin Pharmacol 28 205 212 3987800 10.1007/BF00609693 1:STN:280:DyaL2M7nvFOgtg%3D%3D (Pubitemid 15143785)
20. JM Jacquet F Bressolle M Galtier M Bourrier D Donadio J Jourdan JF Rossi 1990 Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters Cancer Chemother Pharmacol 27 219 225 2265458 10.1007/BF00685716 1:STN:280:DyaK3M%2FptF2luw%3D%3D
21. JM Nabholtz C Falkson D Campos J Szanto M Martin S Chan T Pienkowski J Zaluski T Pinter M Krzakowski D Vorobiof R Leonard I Kennedy N Azli M Murawsky A Riva P Pouillart 2003 Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J Clin Oncol 21 968 975 12637459 10.1200/JCO.2003.04.040 1:CAS:528:DC%2BD2cXpsVGqs7g%3D (Pubitemid 46594123)
22. S Chan G Romieu J Huober T Delozier M Tubiana-Hulin A Schneeweiss A Lluch A Llombart A du Bois R Kreienberg JI Mayordomo A Anton M Harrison A Jones E Carrasco AT Vaury B Frimodt-Moller P Fumoleau 2009 Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer J Clin Oncol 27 1753 1760 19273714 10.1200/JCO.2007.15.8485 1:CAS:528:DC%2BD1MXltlSisr0%3D
23. ES Thomas HL Gomez RK Li HC Chung LE Fein VF Chan J Jassem XB Pivot JV Klimovsky FH de Mendoza B Xu M Campone GL Lerzo RA Peck P Mukhopadhyay LT Vahdat HH Roche 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 5210 5217 17968020 10.1200/JCO.2007.12.6557 1:CAS:528:DC%2BD2sXhsVKnsbzO (Pubitemid 350232252)
24. Lipp HP, Bokemeyer C (1999) Anthracyclines and other intercalating agents. In: Lipp HP (ed) Anticancer drug toxicity: prevention, management and clinical pharmacokinetics. Marcel Dekker, Inc., New York, pp 81-113
25. XP Zhao J Zhong XQ Liu GJ Wang 2007 CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes Acta Pharmacol Sin 28 118 124 17184591 10.1111/j.1745-7254.2007.00484.x (Pubitemid 46046635)
26. JA Sparano AN Makhson VF Semiglazov SA Tjulandin OI Balashova IN Bondarenko NV Bogdanova GM Manikhas GP Oliynychenko VA Chatikhine SH Zhuang L Xiu Z Yuan WR Rackoff 2009 Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study J Clin Oncol 27 4522 4529 19687336 10.1200/JCO.2008.20.5013 1:CAS:528:DC%2BD1MXhtlCns77I
27. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
28. DA Berry C Cirrincione IC Henderson ML Citron DR Budman LJ Goldstein S Martino EA Perez HB Muss L Norton C Hudis EP Winer 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer Jama 295 1658 1667 16609087 10.1001/jama.295.14.1658 1:CAS:528: DC%2BD28XjsVeqs7k%3D
29. KS Albain S Paik L van't Veer 2009 Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays Breast 18 Suppl 3 S141 S145 19914534 10.1016/S0960-9776(09)70290-5
30. S Jones FA Holmes J O'Shaughnessy JL Blum SJ Vukelja KJ McIntyre JE Pippen JH Bordelon RL Kirby J Sandbach WJ Hyman DA Richards RG Mennel KA Boehm WG Meyer L Asmar D Mackey S Riedel H Muss MA Savin 2009 Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735 J Clin Oncol 27 1177 1183 19204201 10.1200/JCO.2008.18.4028 1:CAS:528:DC%2BD1MXktFKhs7c%3D
31. KI Pritchard LE Shepherd FP O'Malley IL Andrulis D Tu VH Bramwell MN Levine 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2103 2111 16707747 10.1056/NEJMoa054504 1:CAS:528: DC%2BD28XkslCku7s%3D (Pubitemid 43736610)
32. Slamon D EW, Robert N, Pienkowski T, Martin M, Rolski J, Chan A, Mackey J, Liu M, Pinter T, Valero V, Falkson C, Fornander T, Shiftan T, Olsen S, Buyse M, Kiskartalyi T, Landreau V, Wilson V, Press M, Crown J (2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (tch) in her2neu positive early breast cancer patients: BCIRG 006 Study. San Antonio Breast Cancer Symposium:Abstract 62